Injective’s Price Surge: A 20% Leap or Merely the Opening Act of a Grand Finale?

Pineapple Financial (NYSE: PAPL), that paragon of fiscal audacity, has escalated its INJ acquisition spree, splurging $2 million on February 19, 2026, under its market cash purchase program. One might call it a treasury play, but let us call it what it is: a Shakespearean love affair with Injective’s ecosystem. This is no fleeting infatuation; it is a marriage of conviction, sealed with $20.79 million in reserves. The DAT dashboard whispers of 7.02 million INJ tokens-proof, if one needed it, that Pineapple’s heart is not merely in the game, but buried in it.






